Abbott Gains Access To Celera R&D For Infectious Disease Assays
This article was originally published in The Gray Sheet
Executive Summary
U.S. clinical lab evaluation of Celera Diagnostics' analyte-specific reagent hepatitis C test by year-end will be among the early milestones of the Applera unit's R&D and marketing agreement with Abbott
You may also be interested in...
AACC In Brief
Clinical lab test final rule: Software glitch delays implementation of Medicare final rule on clinical diagnostic laboratory tests from Nov. 25 to Jan. 1, 2003, American Society for Clinical Laboratory Science Executive VP Elissa Passiment tells participants at American Association for Clinical Chemistry annual meeting July 31 in Orlando. The delay will likely lead to discrepancies between Medicare national coverage decisions and local medical review policies, which may cause over-reimbursement in some instances, she claims. Surplus reimbursement of lab tests by local contractors during the period from Nov. 25 to Jan. 1 can be recouped, Passiment notes...
AACC In Brief
Clinical lab test final rule: Software glitch delays implementation of Medicare final rule on clinical diagnostic laboratory tests from Nov. 25 to Jan. 1, 2003, American Society for Clinical Laboratory Science Executive VP Elissa Passiment tells participants at American Association for Clinical Chemistry annual meeting July 31 in Orlando. The delay will likely lead to discrepancies between Medicare national coverage decisions and local medical review policies, which may cause over-reimbursement in some instances, she claims. Surplus reimbursement of lab tests by local contractors during the period from Nov. 25 to Jan. 1 can be recouped, Passiment notes...
Centerpulse Rebounds 80% In Second Quarter As MDDI Index Drops 17%
Centerpulse stock surged 80.9% in the second quarter as final approval of a hip and knee class-action settlement dissipated the threat of bankruptcy, and the firm decided to divest its non-core businesses to focus on orthopedics. The issue closed at $16.55, up $7.40 for the three months